These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 10888979)
1. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Tsiodras S; Mantzoros C; Hammer S; Samore M Arch Intern Med; 2000 Jul; 160(13):2050-6. PubMed ID: 10888979 [TBL] [Abstract][Full Text] [Related]
2. [Lipodystrophy syndrome in HIV infection]. Hartmann M; Petzoldt D Hautarzt; 2000 Mar; 51(3):159-63. PubMed ID: 10789076 [TBL] [Abstract][Full Text] [Related]
3. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. Carter RJ; Wiener J; Abrams EJ; Farley J; Nesheim S; Palumbo P; Bulterys M; J Acquir Immune Defic Syndr; 2006 Apr; 41(4):453-60. PubMed ID: 16652053 [TBL] [Abstract][Full Text] [Related]
4. [Metabolic complications associated with use of protease inhibitors]. Mosnier-Pudar H Ann Med Interne (Paris); 2000 Jun; 151(4):278-82. PubMed ID: 10922955 [TBL] [Abstract][Full Text] [Related]
5. Tolerability and safety of HIV protease inhibitors in adults. Sax PE; Kumar P J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1111-24. PubMed ID: 15319670 [TBL] [Abstract][Full Text] [Related]
6. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A; Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284 [TBL] [Abstract][Full Text] [Related]
7. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690 [TBL] [Abstract][Full Text] [Related]
8. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors. Sension M; Deckx H AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015 [TBL] [Abstract][Full Text] [Related]
9. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Barbaro G; Di Lorenzo G; Cirelli A; Grisorio B; Lucchini A; Hazra C; Barbarini G Clin Ther; 2003 Sep; 25(9):2405-18. PubMed ID: 14604740 [TBL] [Abstract][Full Text] [Related]
10. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. Yanovski JA; Miller KD; Kino T; Friedman TC; Chrousos GP; Tsigos C; Falloon J J Clin Endocrinol Metab; 1999 Jun; 84(6):1925-31. PubMed ID: 10372688 [TBL] [Abstract][Full Text] [Related]
11. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864 [TBL] [Abstract][Full Text] [Related]
12. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. Chen D; Misra A; Garg A J Clin Endocrinol Metab; 2002 Nov; 87(11):4845-56. PubMed ID: 12414837 [TBL] [Abstract][Full Text] [Related]
13. Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. Heath KV; Chan KJ; Singer J; O'Shaughnessy MV; Montaner JS; Hogg RS Int J Epidemiol; 2002 Oct; 31(5):1016-20. PubMed ID: 12435777 [TBL] [Abstract][Full Text] [Related]
14. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors. Temple ME; Koranyi KI; Nahata MC Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501 [TBL] [Abstract][Full Text] [Related]
15. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. Galli M; Ridolfo AL; Adorni F; Gervasoni C; Ravasio L; Corsico L; Gianelli E; Piazza M; Vaccarezza M; d'Arminio Monforte A; Moroni M J Acquir Immune Defic Syndr; 2002 Jan; 29(1):21-31. PubMed ID: 11782586 [TBL] [Abstract][Full Text] [Related]
16. Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. Bonnet E; Ruidavets JB; Tuech J; Ferrières J; Collet X; Fauvel J; Massip P; Perret B J Clin Endocrinol Metab; 2001 Jan; 86(1):296-302. PubMed ID: 11232015 [TBL] [Abstract][Full Text] [Related]
17. [Dysmetabolic syndrome related to HIV-1 protease inhibitors. Review of the literature and personal data]. Urso R; Croce GF; Tubili C; De Marco M; La Scala P; Luglio D; Narciso P Recenti Prog Med; 2000 Feb; 91(2):78-85. PubMed ID: 10748653 [TBL] [Abstract][Full Text] [Related]
18. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Carr A; Samaras K; Thorisdottir A; Kaufmann GR; Chisholm DJ; Cooper DA Lancet; 1999 Jun; 353(9170):2093-9. PubMed ID: 10382692 [TBL] [Abstract][Full Text] [Related]
19. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Ergun-Longmire B; Lin-Su K; Dunn AM; Chan L; Ham K; Sison C; Stavola J; Vogiatzi MG Endocr Pract; 2006; 12(5):514-21. PubMed ID: 17014060 [TBL] [Abstract][Full Text] [Related]